L-type Ca++ CP α1D Inhibitors

Nifedipine, nimodipine, felodipine, isradipine, nicardipine, amlodipine, lacidipine, and lercanidipine, all dihydropyridine derivatives, inhibit the influx of calcium ions into vascular smooth muscle during depolarization. This impedes calcium-dependent myocyte and vascular smooth muscle contraction and dilates the main coronary and systemic arteries. By influencing calcium ion conduction, these inhibitors indirectly affect the function of the L-type Ca++ CP α1D. On the other hand, verapamil and gallopamil, phenylalkylamine derivatives, and diltiazem, a benzothiazepine derivative, inhibit the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This action on the calcium influx indirectly modulates the L-type Ca++ CP α1D.

Bepridil, which does not fall into the above subclasses, also inhibits the influx of extracellular calcium through myocardial and vascular membrane pores. This decrease in myocardial contractility and oxygen demand, combined with the dilation of the coronary and systemic arteries, indirectly modifies the activity of the L-type Ca++ CP α1D. Through these mechanisms, L-type Ca++ CP α1D inhibitors can have a profound influence on the function of this protein indirectly. Although their primary targets are calcium channels, their impact on calcium ion conduction and influx extends to the L-type Ca++ CP α1D, underscoring the interconnected nature of cellular signaling pathways. The action of these inhibitors exemplifies how manipulation of one molecular component in a cell can propagate through the network of signaling pathways to affect various proteins and cellular functions.